 |
|
|
|
 |
|
|
| Article 1 to 10 out of 54
|
|
-
Characterization of grapevine transposons furthers understanding of in vino variety
(04 Sep 2008)
The grapevine (Vitis vinifera) is a widely cultivated crop that has been subjected to intensive breeding since the Neolithic period (from ~10,500 to ~6,000 years ago). The domestication of grapevine has undergone a selection for traits ......
-
Extreme competive sports: A fitness test for DNA
(25 Aug 2008)
Unusually high levels of physical exertion do cause oxidative stress, but this does not result in any long-term damage to DNA. This is just one of the many outcomes revealed by an extraordinary research project funded by the Austrian Science ......
-
AFFiRiS reaches milestone in clinical trial of Alzheimer's vaccine
(18 Jul 2008)
In the clinical phase I trial AFF001, AFFiRiS GmbH has now recruited the 24 Alzheimer patients planned for this trial. The trial aims to investigate the tolerability and safety of an Alzheimer's vaccine (AFFITOPE AD01). In the trial, all ......
-
Intercell: IOMAI Acquisition granted clearance by US Authorities
(15 Jul 2008)
Intercell AG announced that, following review by the United States Securities and Exchange Commission (SEC), Iomai Corporation filed a definitive proxy statement on July 10, 2008 for Iomai stockholders regarding the proposed acquisition by ......
-
Study against pandemic influenza with vaccine deltaFLU
(11 Jul 2008)
Avir Green Hills Biotechnology starts a clinical phase I study with its intranasal vaccine deltaFLU against pandemic influenza. This novel generation of a live-attenuated vaccine based on the deletion of the NS1 gene has shown superior ......
-
Allium Medical expands in Europe, signs exclusive distribution deals in Germany, Austria and Benelux
(10 Jul 2008)
MenkeMed in Germany and Austria and Ecce Dutoit in the Benelux
Allium Medical Group, developer and manufacturer of anatomically and functionally compatible, dynamic, large-caliber, removable stents, announced that it has signed exclusive distribution deals for both its ureteral and biliary stents with ......
-
Mucoviscidosis Therapy Gets Closer
(27 Jun 2008)
Axentis Pharma takes over patents and continues development of innovative platform technology
The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred to Swiss biotech company Axentis Pharma AG. The company has acquired the rights from an Austrian firm that has made a vital ......
-
ProtAffin AG strengthens Scientific Advisory Board
(12 Jun 2008)
ProtAffin AG announced that it has strengthened its Scientific Advisory Board with the appointment of Dr. Antal Rot. Dr. Rot is currently Group Head at the Novartis Institute of Biomedical Research (NIBR) in Vienna, Austria and is a key figure ......
-
Intercell AG to acquire Iomai Corporation to expand late stage product pipeline and strengthen leadership in vaccine innovation
(14 May 2008)
Intercell AG and Iomai Corporation announced that they have entered into a definitive agreement pursuant to which Intercell will acquire Iomai for USD 6.60 per share representing a fully diluted equity value of approximately USD 189 million ......
-
Intercell and its partner institutions are awarded an EU grant for targeting research and novel treatments of fungal infections
(24 Apr 2008)
Intercell further strengthens its fungal franchise by supporting the new Christian Doppler Laboratory
Intercell AG announced that the joint project to develop protective treatments against fungal infections was awarded an EUgrant. Intercell is coordinating a European consortium of three academic and commercial partners within the "CanVac" ......
|
|
|
|
|
Top
